Hypofractionated image-guided breath-hold SABR (Stereotactic Ablative Body Radiotherapy) of liver metastases – clinical results

Judit Boda-Heggemann1,5*, Dietmar Dinter2, Christel Weiss3, Anian Frauenfeld1, Kerstin Siebenlist1, Ulrike Attenberger2, Martine Ottstadt1, Frank Schneider1, Ralf-Dieter Hofheinz4, Frederik Wenz1 and Frank Lohr1

Abstract

**Purpose:** Stereotactic Ablative Body Radiotherapy (SABR) is a non-invasive therapy option for inoperable liver oligometastases. Outcome and toxicity were retrospectively evaluated in a single-institution patient cohort who had undergone ultrasound-guided breath-hold SABR.

**Patients and methods:** 19 patients with liver metastases of various primary tumors consecutively treated with SABR (image-guidance with stereotactic ultrasound in combination with computer-controlled breath-hold) were analysed regarding overall-survival (OS), progression-free-survival (PFS), progression pattern, local control (LC), acute and late toxicity.

**Results:** PTV (planning target volume)-size was 108 ± 109 cm³ (median 67.4 cm³). BED2 (Biologically effective dose in 2 Gy fraction) was 83.3 ± 26.2 Gy (median 78 Gy). Median follow-up and median OS were 12 months. Actuarial 2-year-OS-rate was 31%. Median PFS was 4 months, actuarial 1-year-PFS-rate was 20%. Site of first progression was predominantly distant. Regression of irradiated lesions was observed in 84% (median time to detection of regression was 2 months). Actuarial 6-month-LC-rate was 92%, 1- and 2-years-LC-rate 57%, respectively. BED2 influenced LC. When a cut-off of BED2 = 78 Gy was used, the higher BED2 values resulted in improved local control with a statistical trend to significance (p = 0.0999). Larger PTV-sizes, inversely correlated with applied dose, resulted in lower local control, also with a trend to significance (p-value = 0.08) when a volume cut-off of 67 cm³ was used. No local relapse was observed at PTV-sizes < 67 cm³ and BED2 > 78 Gy. No acute clinical toxicity ≥°2 was observed. Late toxicity was also ≤°2 with the exception of one gastrointestinal bleeding-episode 1 year post-SABR. A statistically significant elevation in the acute phase was observed for alkaline-phosphatase; in the chronic phase for alkaline-phosphatase, bilirubine, cholinesterase and C-reactive protein.

**Conclusions:** A trend to statistically significant correlation of local progression was observed for BED2 and PTV-size. Dose-levels BED2 > 78 Gy cannot be reached in large lesions constituting a significant fraction of this series. Image-guided SABR (igSABR) is therefore an effective non-invasive treatment modality with low toxicity in patients with small inoperable liver metastases.

**Keywords:** Hypofractionated image-guided breath-hold SABR, Liver metastases, Local control, Survival, Toxicity
Background/Introduction
Standard therapy for solitary liver metastases is surgical resection [1]. For medically or technically inoperable patients, therapy options include radiofrequency-, microwave- and cryo-/laser- ablation, alcohol-injection, transarterial chemoembolisation and stereotactic ablative radiotherapy (SABR) [2,3]. SABR is the only truly non-invasive approach, combining high efficacy with minimal side effects in the oligometastatic situation [4].

Dose-escalation has improved local control [5]. High-dose liver-SABR is a technical challenge because of respiration-induced movement and vicinity of radiosensitive Organs-At-Risk (OAR [6]). The main problems are precise tumor immobilisation as well as fast and reliable visualisation and localisation of the lesions. Irradiation during free-breathing with the Internal Target Volume concept and abdominal compression would require a relatively larger PTV compared to breath-hold defined PTV (Planning Target Volume, due to breathing motion [7]).

Breath-hold techniques enable tumor immobilisation and the delivery of high doses to the PTV while maximally sparing the OARs [8]. Computer-controlled breath-hold with the ABC®,-system (Active Breathing Coordinator, Eleka, Crawley, U.K.) in combination with daily image-guidance has been shown to be feasible for liver targets [9]. Upper abdominal tumors can be rapidly visualised and localised with stereotactic ultrasound (B-mode acquisition and targeting, BAT®, Nomos) [10-12], either directly or relying on surrogate structures (liver capsule, vessels), or with on-board cone-beam-CT (CBCT) [13] with a repeat breath-hold approach [14].

Data of large patient cohorts on local control (LC) and survival after liver SABR are relatively rare due to lack of large randomised studies. Given the novelty of SABR, studies (both prospective and retrospective) with long-term follow-up data are still rare.

In this retrospective evaluation, we intended to assess outcome and toxicity in a unique single-institution series of patients who received volume image-guided breath-hold liver SABR.

Overall-survival (OS), progression-free-survival (PFS), local control (LC), acute and late toxicity based on clinical and laboratory parameters and CTC/LENT-SOMA (Common Toxicity Criteria/ Late Effects on Normal Tissues; Subjective Objective Management Analysis) scales were evaluated.

Patients and methods
Patients
Between 2005–2010, 22 lesions in 19 consecutive patients (15 male, 4 female; median age 69yrs, range 39-87yrs) were irradiated (one re-irradiation, in 2 patients 2 lesions in 1 PTV) after informed consent. All lesions were liver metastases of various primary tumors (10 colorectal, 1 prostate, 2 breast, 2 melanoma, 1 GIST (Gastrointestinal Stromal Tumor), 1 oesophagus, 1 hepatocellular carcinoma, 1 NSCLC (Non-Small-Cell Lung Cancer)) which were considered to be technically or medically inoperable by an interdisciplinary tumor-conference. The cohort can be characterised by a relatively large number of patients with poor prognosis (5 patients with extrahepatic metastases and 2 patients with uncontrolled primaries).

Radiotherapy planning and treatment
Planning CT scans were acquired with a spiral-CT (Somatom Emotion, thereafter Somatom Volume Zoom; Siemens, Erlangen, Germany) with i.v. contrast, in the portal-venous phase after an initial patient training session in inspiratory breath-hold at approximately 70% of vital capacity with ABC® [12]. Radiotherapy planning was initially performed as 3-dimensional conformal RadioTherapy (3D-CRT) with OTP, Theranostic GmbH, Solingen, Germany and thereafter with Intensity Modulated RadioTherapy (IMRT) with Monaco®, Elekta. A pre-therapeutic MRI or PET-CT was performed and the information was used during planning for GTV (Gross Tumor Volume) definition. PTV was calculated from GTV by adding a 5 mm margin radially and 10 mm in the craniocaudal direction to compensate residual intrafractional error of the ABC®-based positioning [15].

Organ contours and surrogate structures needed for ultrasound-based image guidance (portal vein, liver veins, and liver capsule) were identified by a physician [10,12] and were exported to BAT®

Dose prescription was initially performed to the isocenter (3D-CRT, typically in the vicinity of the median dose) and later as the median dose in the PTV (IMRT) with the 90% isodose line covering the PTV. Dose constraints for OAR were as follows: mean dose to each kidney was restricted to 10 Gy, maximal dose in the spinal cord to 25 Gy. Hot spots in >0.5 cm³ of hollow organs (stomach/small intestine/oesophagus) were restricted to a maximum of 8 Gy/fraction for treatments with ≤3 fractions and a maximum of 6 Gy/fraction for treatments with 5 fractions. 50% of healthy liver tissue was kept below 10 Gy [16]. Implementing results from published literature reports regarding dose escalation and fractionation, dose to the patients was adjusted during the reported period and varied between single-fraction doses of 24-30 Gy initially (depending on tumor and liver volume) and various hypofractionated regimens with the current, final protocol prescribing 5x12 Gy every other day.

Biologically effective dose in 2 Gy fractions (BED2) was calculated using the linear-quadratic model with an assumed \(\alpha/\beta\) ratio of 10 as described [6]:

\[
\text{BED2} = D + \frac{D^2}{\alpha/\beta} \approx D + 2D^2/\alpha/\beta \quad \text{for} \quad D < \alpha/\beta
\]
Patients were treated on a linac with 6MV photons (Synergy®, Elekta). Daily image-guidance was performed with BAT® and beginning in 2005 with additional CBCT with image acquisition in repeated breath-hold (XVI®, X-Ray Volume Imaging, Elekta; [17]). CT-structures, contours of PTV and OAR/surrogate structures were imported into the BAT® and XVI®-system as 3D structures in DICOM (Digital Imaging and Communication in Medicine) format. Although the lesion to be treated could not always directly be visualized by ultrasound, the liver as a whole as well as surrogate structures (portal vein, liver veins) could be precisely visualized and matched and served as surrogates for positioning of the target [10,12] (Figure 1A-D). No implanted fiducials were used for EPID localisation to establish a completely non-invasive treatment modality [10].

Linac, BAT® and ABC® were not connected by interfaces. Breath-hold and imaging or beam were synchronized manually. When CBCT was used (used for initial positioning/assessment of overall geometric situation and rarely exclusively if BAT® was not available, Figure 1E-F), planning-CT images were matched online with the daily CBCT images acquired in repeat breath-hold [17] using manual fusion and with respect to soft-tissue anatomy. On-line surveillance of breath-hold was performed based on the continuous acquisition of MV-frames (EPID; Electronic Portal Imaging Device) during irradiation allowing position verification of the diaphragm. Intrafractional error was controlled/corrected with BAT® at least two times per fraction.

Patient follow-up (FU) was scheduled 6 weeks after radiotherapy and every 3 months thereafter with clinical examination, liver-MRI with i.v. contrast (or CT/PET-CT, if MRI contraindicated) and laboratory values. An assessment of tumor response was performed using the RECIST (Response Evaluation and Criteria in Solid Tumors) criteria. Response was graded as complete response (CR), partial response (PR), stable disease (SD) or progression.

Acute toxicity was defined as symptoms observed in the first 90 days after radiotherapy, with later symptoms being scored as late toxicity.

Data analysis
OS (Overall-Survival), PFS (Progression-Free-Survival) and LC (Local Control) were recorded and subject to actuarial analysis. Acute (first 90 days) and late toxicity (>90 days) was evaluated based on clinical symptoms and laboratory values (graded based on the CTC-scale in the acute phase and on the LENT-SOMA criteria in the late phase.

Recorded clinical endpoints/symptoms were general condition, abdominal pain, appetite, nausea, vomiting, fever and skin symptoms for assessing acute toxicity; abdominal pain, hepatomegaly, edema, weight gain due to edema/ascites, vigilance, bleedings, ascites and rib fracture for late toxicity.

The following laboratory values were analysed: ALAT (alanine-aminotransferase), ASAT (aspartate-aminotransferase), GGT (gamma-glutamyl-transferase), LDH (lactate-dehydrogenase), AP (alkaline-phosphatase), BR (bilirubine), aPTT (activated partial thromboplastine-time), thrombocyte-count, serum albumin, CHE (cholinesterase), prothrombin activity, blood urea, CRP (C-reactive-protein).

PTV-coverage was analysed based on relevant parameters (D99 (dose encompassing 99% of the PTV), minimal, maximal, mean and median PTV-dose. Volume of healthy liver tissue was documented. Depth of breath-hold and breath-hold duration was also evaluated.

Statistics
Statistical analysis was performed with the SAS-software, release 9.01 (SAS, Cary, NC, USA). OS was calculated from the day of irradiation until either the day of death (event) or the day of the last FU (follow-up, censored data). PFS was calculated from the day of irradiation

![Figure 1 Daily positioning with BAT®. Before (A-B) and after (C-D) position correction. Surrogate structures and PTV are marked with colors: orange, liver; green, PTV; blue, portal vein; red, liver veins. E-F: Alternative repeat breath-hold positioning with CBCT. Green, CBCT; magenta, planning-CT.](image-url)
until either the day of relapse or death (events) or the last FU without relapse (censored data when at the last FU the patient lived without any evidence of progression). LC was calculated from the day of irradiation until either the day of local progression or death (event) or the last FU without local progression (censored data when at the last FU the patient lived without any evidence of local progression). Kaplan-Meier-curves for OS, PFS and LC were calculated in order to assess median survival/control times. Correlation of local progression as a binary parameter and PTV size and BED2 was analysed with the logistic regression test. Correlation of the local control time with PTV size and BED2 was analysed by the Kaplan-Meier log-rank test. Differences between pre- and post-therapeutic laboratory values were tested using the Dunnett-test. Test results were considered significant when p-values were <0.05.

Results

Radiotherapy data

All patients managed to achieve sufficient repeat breath-hold with ABC° for an IMRT (3 patients) or 3DCRT (16 patients) radiotherapy session. Breath-hold time was 17.2 ± 3.6 seconds. Depth of breath-hold was 1.5 ± 0.4 litres (threshold value in ABC°). Volume of healthy liver tissue was 1401 ± 350 cm³.

BED2 was 83.3 ± 26.2 Gy (median 78 Gy, range 44-150 Gy). 7 patients were treated with a BED2 of ≤78 Gy, 12 patients with a BED2 of ≥78 Gy. PTV dose-data for different fractionation schedules are summarised in Table 1. PTV-size was 108 ± 110 cm³ (median 67.4 cm³, range 11-419 cm³).

Follow-up (FU), Overall-Survival (OS), Progression-free-survival (PFS) and Local Control (LC)

Median FU was 12 months (14 ± 12 months; MV ± SD, mean value ± standard deviation). Median FU was 12 months (18 ± 15 months) for living patients. 5 patients are alive, 13 patients have died and one patient has been lost to FU (released from jail, not traceable).

Actuarial median OS was 12 months (15 ± 13 months; Figure 2A). Actuarial 2-year OS was 31%. Cause of death was systemic metastases outside the liver in 5 patients, progression of the primary tumor (oesophagus/colorectal) in 5 patients, an episode of acute gastrointestinal bleeding in one patient and hepatic insufficiency in one patient, mainly induced by hemochromatosis and liver cirrhosis that had been prevalent over several years. In one patient, the cause of death could not be determined unequivocally but brain metastases were suspected clinically when therapeutic measures were halted because of deteriorating general condition.

Median PFS was 4 months (8 ± 8 months; Figure 2B), actuarial 1-year PFS was 20%. Progression pattern was mainly distant (a total 17 patients experienced systemic progression; 10 patients had a second liver metastasis, 9 patients had extrahepatic distant metastases in brain/lung/bones/kidney/adrenal-gland/spleen/peritoneum/abdominal-wall/abdominal-lymph nodes).

Median LC has not yet been reached. Actuarial 6-month LC-rate was 92%, 2-year LC rate was 57% (Figure 2C). Most patients died due to systemic metastases or progress of the primary (77%) with locally controlled irradiated lesions.

Correlation of Local Progression as a binary parameter and PTV size and BED2 was analysed with the logistic regression test. PTV size has shown a trend towards lower local control in larger lesions (p = 0.0894). However, correlation of local control time to PTV size (cut-off 67ccm) with the Kaplan Meier Log-rank test has not shown statistical significance (p = 0.2412; Figure 3A).

Local recurrences were only observed for patients receiving a BED2 ≤78 Gy (5 patients). BED2 did not show a significant correlation in the logistic regression (p = 0.1926) but a trend to significance at a dose cut-off of 78 Gy with the Kaplan Meier log-rank test (p = 0.0999; Figure 3B).

In 16 patients, size-reduction of the irradiated lesion was observed, in 3 patients, lesions remained unchanged. Median time to response was 2 months (3 ± 1 months, typically at first reported FU). Complete response of the

---

Table 1 Mean, median, minimal and maximal absolute doses to the PTV for different fractionation regimens

| PTV dose parameter | single-fraction (SABR n = 12) | 2 fractions (n = 2) | 3 fractions (n = 3) | 5 fractions (n = 5) |
|--------------------|------------------------------|--------------------|--------------------|--------------------|
|                   | (Mean value ± Standard deviation) | (Mean value ± Standard deviation) | (Mean value ± Standard deviation) | (Mean value ± Standard deviation) |
| D<sub>mean</sub>   | 26.07 ± 1.81                 | 27.16 ± 3.87       | 33.92 ± 1.37       | 59.51 ± 0.58       |
| D<sub>median</sub>| 26.11 ± 1.79                 | 27.12 ± 3.88       | 34.34 ± 1.47       | 59.89 ± 0.66       |
| D<sub>max</sub>   | 23.9 ± 1.85                  | 21.23 ± 3.31       | 26.56 ± 2.46       | 50.92 ± 8.00       |
| D<sub>99</sub>    | 27.26 ± 2.06                 | 29.3 ± 5.44        | 36.3 ± 0.89        | 62.48 ± 1.24       |
| D<sub>90</sub>    | 24.2 ± 2.62                  | 25.65 ± 4.0        | 32.6 ± 2.55        | 57.54 ± 3.19       |

D<sub>max</sub>: Dose encompassing 99% of the PTV.

Abbreviations: D<sub>max</sub>, minimal dose; D<sub>max</sub>, maximal dose; D<sub>median</sub>, median dose; D<sub>mean</sub>, mean dose; PTV, Planning Target Volume.
Figure 2 Kaplan-Meier-curves for all patients. A.) Overall-survival. B.) Progression-free-survival. C.) Local control.
irradiated lesion was observed in 5 cases. Later local progression after initial regression was observed in 5 patients after a median of 10 months.

A representative patient example is shown in Figure 4.

**Acute toxicity**

No acute toxicity > CTC grade 2 was observed. The following symptoms were detected: slight upper-abdominal pain (3 patients), appetite loss (4 patients), nausea (3 patients), slight vomiting (2 patients) and fatigue (4 patients). Fever was observed in only 1 patient; however, this was considered a dexamethasone side-effect.

One patient developed a clinically indolent but radiologically evident and lab-proven cholangitis, which was successfully treated with interventional endoscopy. No clinical signs of pneumonitis and no acute gastrointestinal bleedings were observed.

A significant elevation compared to pre-therapeutic values in the acute phase was observed only for AP (p = .0274), indicating an intrahepatic cholestasis, which, however, in most patients was clinically unapparent (in one patient radiologically detectable). ALAT, ASAT, GGT, LDH, BR, aPTT, thrombocyte count, albumin, CHE, prothrombin activity, blood urea and CRP did not show significant changes.

**Chronic toxicity**

Late toxicity was difficult to analyse in this cohort of patients with advanced tumor stages due to progressive disease causing symptoms similar to radiation-associated processes/radiation sequelae. Several patients who developed multiple liver metastases, suffered from ascites, edema, weight gain and other signs of hepatic insufficiency. Patients without hepatic progression did not develop any chronic toxicity regarding the upper abdomen. No rib fractures were observed.

One patient experienced an episode of endoscopically confirmed gastrointestinal bleeding 1 year post-igSABR. An anatomical correlation of the endoscopic report about the bleeding with the radiation plan was performed. No spatial correlation could be found, however, a “matching” of an endoscopy report with planning CT is certainly not possible.

A significant elevation compared to pre-therapeutic values in the chronic phase was observed for AP (p = 0.0016), BR (p = 0.0222), CHE (p = 0.0056) and CRP (p = 0.0320). A trend to significance was observed for GGT (p = 0.0673). ALAT, ASAT, LDH, aPTT, thrombocytes, albumine, prothrombin activity and blood urea did not show significant changes.

**Discussion**

In SABR of liver metastases, dose escalation has been shown to be essential to increase local control [1]. Technical improvement of planning and delivery have enabled dose escalation, within the confines of liver tolerance dose-volume constraints [18]. A relatively high interfractional accuracy was achievable with frame-based positioning in free-breathing with abdominal compression. Daily soft-tissue image-guided frameless stereotaxy allows fast imaging in breath-hold and in the future even tracking [10,12,14]. There are no large prospective studies evaluating the clinical results of SABR of the liver. The present cohort is the first clinically reported series of igSABR using an ultrasound-guided computer-controlled breath-hold setup.

Radiation-induced change in the liver include Radiation-Induced Liver Disease (RILD) with a syndrome of anicteric ascites and hepatomegaly, elevation
of transaminases and reactivation of virus hepatitis [20]. Despite the detected histological and radiological radiation reactions, clinical symptoms after liver SABR have been reported in several studies to be low with maximum side effect reaching grade 3 [3]. Similar to literature data, clinical acute and late toxicity did not exceed CTC/LENT-SOMA grade 2 in our collective. Solely one episode of gastric bleeding 1-year post-SBRT was detected. Based on localisation of the treated lesion and the source of bleeding, association with IgSABR is unlikely but cannot be excluded with certainty in retrospect.

Outcome cannot be compared according to primary malignancy in the published series because of small numbers of patients treated for individual disease. Varying fractionation schedules in different series and also within one series, however, can be compared calculating BED2. In addition, most studies evaluate mixed cohorts of lung and liver SABR without a clear differentiation of these two populations.

Lesions receiving BED2 < 78 Gy did not achieve satisfactory local control in this series. We analysed the available studies in the literature also with calculating BED2 and compared these to our data (Table 2, [5,21-26]). Comparing all published studies, a maximum 1-yr local control rates of 57% was reported, if BED2 < 50 Gy was applied in large PTVs (range up to >400ccm).

Our cohort with mixed primary tumor entities represented an unfavourable patient subset (several patients had extensive metastatic disease). Fractionation schedule and nominal doses varied over the evaluated period, reflecting escalation of published doses. Doses used initially can be regarded as too low in retrospect with the current knowledge. The daily repositioning technique used for this series was unique (computer-controlled breath hold in combination with sonographic imaging) compared to similar analyses in the literature. Median survival of 12 months and a 1-yr LC rate of 57% are, however, comparable to literature data. Due to the relatively small and heterogeneous collective, we could not establish a formal dose-effect relationship. No local relapse was observed at PTV-sizes smaller as 67 cm³ and doses >78 Gy BED2 and a trend to statistically significant correlation was observed for both parameters. This dose level could not be reached due to threshold doses in large lesions constituting a significant fraction of this series. That the results are not highly statistically significant, is probably due to the small patient number and relatively large range of applied BED2 (between 44-150 Gy) and PTV-sizes (between 21-419 cm³).

**Table 2** Comparison of available studies in the literature

| Study                  | Irradiated liver metastases (n) | Nominal total dose/single dose (Gy) | BED2 (Gy) | Lesion size (ccm) | Median FU (months) | 1-year LC rate (%) |
|------------------------|---------------------------------|-------------------------------------|-----------|-------------------|--------------------|-------------------|
| Katz et al., 2007 [21] | 69                              | 30-55/2-6                           | 40-73*    | 0.1-950*          | 14.5               | 76                |
| McCammon et al., 2009 [5] | 81                             | 3 dose levels:                      | 3 levels*| 2.8-370           | 8.2                |
|                        |                                 | 1) < 36/12                          | 1) 39     |
|                        |                                 | 2) 36-54/12-18                      | 2) 39-58  |
|                        |                                 | 3) 54/18                            | 3) 58     |
| Milano et al., 2008 [22] | 121                            | 10-20/10-20                         | 16-50     | 0.2-422           | Not stated         | 57                |
| Goodmann et al., 2010 [23] | 40                             | 18-30/18-30                         | 42-100*   | 0.8-146           | 17                 | 77                |
| Iwata et al., 2010 [24] | 12                              | 50-55/5-5.5                         | 62-71*    | 0.9-22*           | 14.5               | 86                |
| Rusthoven et al., 2009 [25] | 63                             | 36-60/12-20                         | 66-150*   | <113*             | 16                 | 95                |
| Lee et al., 2009 [26]   | 68                              | 42-60/7-10                          | 59-100*   | 1.19-3000         | 10.8               | 71                |
| Current series JBH et al. | 22                             | 24-60/24-12                         | 44-150    | 11-419            | 12                 | 57                |

BED2 and PTV volumes were calculated by JBH et al. (V = 4/3r³; median/range) in the cases marked with *. 

---

**Figure 4** Radiation plan, pretreatment- and posttreatment MRI of a patient with two small liver metastases of a melanoma treated with 1x26Gy in 1 PTV. The lesions remain locally controlled (follow-up of 4 years).
Steep dose gradients and precise intrafractional repositioning before each fraction is possible with the currently available commercial methods. Non-invasive markerless intrafractional monitoring of tumor position is, however, not yet possible with commercially available systems with ultrasound-based online monitoring being developed [27]. Precise positioning and online surveillance will probably allow further reduction of safety margins (for an average CTV size of 113cm^3 the reduction of safety margin of 5 mm would spare 66ccm healthy liver tissue). This would enable irradiation of larger lesions with higher doses.

Results may further be improved by parallel administration of chemotherapeutic agents for radiosensitization. Large studies are needed to optimize clinical outcome and characterise radiological and clinical side effects.

These data show that, if the application technique, lesion size and dose to OAR allow the application of doses approaching the ablation threshold dose calculated by Fowler and Tome [28], then SABR of the liver with photons is an effective, non-invasive and safe treatment method. Similar results have been observed for SABR of the lung [29,30]. For large lesions (>70 cm^3), if no BED2 > 80 Gy can be reached without a high risk of side effects, results are still not satisfactory. Limiting factor for dose escalation in liver SABR is the radiation tolerance of healthy liver tissue. After introduction of modern highly precise techniques with steep dose gradients (VMAT (Volumetric Modulated Arc Therapy) [31,32], IMRT) with daily 3D image guidance, maximal efficacy of photon-based SBRT has been reached.

New radiotherapy techniques may provide further optimization of dose distributions [33]. Detection of intrafractional motion by online tracking may facilitate applying sufficiently high doses to larger lesions.

Conclusions
Breath-hold image guided SABR of liver metastases is an effective and safe treatment modality for inoperable liver metastases.

No local relapse was observed at PTV-sizes < 67 cm^3 and BED2 > 78 Gy and a trend to statistically significant correlation with local control was observed for both parameters. However, this dose level cannot be reached in large lesions constituting a significant fraction of this series.

Competing interest
This work was in part supported by a grant from Elekta Inc. and Nomos. There are no conflicts of interest.

Acknowledgements
We thank all referring physicians (Dr. Plöger/Mannheim; Dr. Massner/Frankenthal; Prof. Vogl/Frankfurt; Dr. Uhl/Maxdorf; Dr. Brust/Mannheim; Dr. Goldschmidt/Mannheim; Dr. Wittmann/Mannheim) for providing clinical information/laboratory values. We thank Marat Bernhard, Iris Löb und Beate Küpper for providing excellent technical support with ABC® and CBCT. We thank Prof. Zoltan Boda for scientific discussion of the laboratory values. We thank Erika Filip for management of archived patient data. Parts of these studies were supported by a research grant from Elekta Inc and Nomos as well as from BMBF (Bundesministerium für Bildung und Forschung, Germany).

The first author is supported by the “Ministerium für Bildung und Forschung, Baden-Württemberg” and the ESF (European Social Fonds).

Authors’ contributions
JBH, AF: data acquisition. JBH: manuscript drafting. DD, UA: interpretation of radiological data (MRI, CT). CW: statistical evaluation. KS, FL: radiation treatment planning. FS: radiation treatment planning. QA, RH: chemotherapy administration, treatment follow-up. MO: interpretation of laboratory data. FW, FL, JBH and all others: final approval of MS text. All authors read and approved the final manuscript.

Received: 9 January 2012 Accepted: 18 June 2012 Published: 18 June 2012

References
1. Timmerman RD, Bizekis CS, Pass HI, et al: Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin 2009, 59:145–170.
2. Bijmolt H, Lah I, Nauts L, Svanstrom R: Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator: Clinical experience of the first thirty-one patients. Acta Oncol 1995, 34:861–870.
3. Herfarth KK, Debus J, Lehr F, et al: Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/I trial. J Clin Oncol 2001, 19:164–170.
4. Kavanagh BD, Schefter TE, Cardenes HR, et al: Interim analysis of a prospective phase I/I trial of SBRT for liver metastases. Acta Oncol 2006, 45:848–855.
5. McCormon R, Schefter TE, Gaspar LE, Zaemisch R, Gavaldah D, Kavanagh B: Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2009, 73:112–118.
6. Milano MT, Conrste LS, Okeniit P: Normal tissue toxicity after small field hypofractionated stereotactic body radiation. Radiat Oncol 2008, 3:36.
7. Guckenberger M, Sweeney RA, Wilbert J, et al: Image-guided radiotherapy for liver cancer using respiratory-correlated computed tomography and cone-beam computed tomography. Int J Radiat Oncol Biol Phys 2008, 71:297–304.
8. Wong MJ, Sharpe MB, Jaffay DA, et al: The use of active breathing control (ABC) to reduce margin for breathing motion. Int J Radiat Oncol Biol Phys 1999, 44:911–919.
9. Dawson LA, Eccles C, Bissonnette JP, Brock KK: Accuracy of daily image guidance for hypofractionated liver radiotherapy with active breathing control. Int J Radiat Oncol Biol Phys 2005, 62:1247–1252.
10. Fuss M, Sailer B, Cavanaugh SJ, et al: Daily ultrasound-based image-guided targeting for radiotherapy of upper abdominal malignancies. Int J Radiat Oncol Biol Phys 2004, 59:1245–1256.
11. Boda-Heggemann J, Mennemeyer P, Wertz H, et al: Accuracy of ultrasound-based image guidance for daily positioning of the upper abdomen: an online comparison with cone beam CT. Int J Radiat Oncol Biol Phys 2009, 74:892–897.
12. Boda-Heggemann J, Walter C, Mai S, et al: Frameless stereotactic radiosurgery of a solitary liver metastasis using active breathing control and stereotactic ultrasound. Strahlenther Onkol 2006, 182:216–221.

13. Boda-Heggemann J, Lohr F, Wenzi F, Flentje M, Guckenberger M. kV cone-beam CT-based IGRT: a clinical review. Strahlenther Onkol 2011, 187:289–291.

14. Boda-Heggemann J, Fleckenstein J, Lohr F, et al: Multiple breath-hold CBCT for online image guided radiotherapy of lung tumors: simulation with a dynamic phantom and first patient data. Radiother Oncol 2011, 98:309–316.

15. Koshani R, Balter JM, Hayman JA, Henning GT, van Herk M: Short-term and long-term reproducibility of lung tumor position using active breathing control (ABC). Int J Radiat Oncol Biol Phys 2006, 65:1553–1559.

16. Eccles CL, Bissinnette JP, Craig T, Taremi M, Wu X, Dawson LA: Treatment planning study to determine potential benefit of intensity-modulated radiotherapy versus conformal radiotherapy for unresectable hepatic malignancies. Int J Radiat Oncol Biol Phys 2008, 72:582–588.

17. Boda-Heggemann J, Kohler FM, Kupper B, et al: Partial volume tolerance of the liver to single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 2010, 78:1247–1255.

18. Molinelli S, de Pooter J, Mendez Romero A, et al: Simultaneous tumour dose escalation and liver sparing in Stereotactic Body Radiation Therapy (SBRT) for liver tumours due to CTV-to-PTV margin reduction. Radiother Oncol 2008, 87:432–438.

19. Case RB, Sonke JJ, Moseley DJ, Kim J, Brock JK, Dawson LA: Inter- and intrafraction variability in liver position in non-breath-hold stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2009, 75:302–308.

20. Dawson LA, Ten Haken RK: Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 2005, 15:279–283.

21. Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P: Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys 2007, 67:793–798.

22. Milano MT, Katz AW, Schell MC, Philip A, Okunieff P: Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72:1516–1522.

23. Goodman KA, Wiegner EA, Matuven KE, et al: Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 2010, 78:486–493.

24. Ivata H, Shibamoto Y, Hashiaume C, et al: Hypofractionated stereotactic body radiotherapy for primary and metastatic liver tumors using the novalis image-guided system: preliminary results regarding efficacy and toxicity. Technol Cancer Res Treat 2010, 9:619–627.

25. Rutschoven KE, Kavanagh BD, Cardenes H, et al: Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009, 27:1572–1578.

26. Lee MT, Kim JJ, Dinnellwell R, et al: Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009, 27:1585–1591.

27. Hsu A, Miller NR, Evans PM, Bambar JC, Webb S: Feasibility of using ultrasound for real-time tracking during radiotherapy. Med Phys 2005, 32:1500–1512.

28. Fowler JR, Tome WA, Fenwick JD, Mehta MP: A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys 2004, 60:1241–1256.

29. Scorsetti M, Mancosu P, Navarria P, et al: Stereotactic body radiation therapy (SBRT) for adrenal metastases: a feasibility study of advanced techniques with modulated photons and protons. Strahlenther Onkol 2011, 187:252–244.

30. Timmerman RD, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bjug J, Videtic G, Chey H: Stereotactic Body Radiation Therapy for Medically Inoperable Early-stage Lung Cancer Patients: Analysis of RTOG 0236. JCOBP 2009, 75:53.

31. Eppinga W, Lagerwaard F, Verbakel W, Slotman B, Senan S: Volumetric modulated arc therapy for advanced pancreatic cancer. Strahlenther Onkol 2010, 186:382–387.

32. Steier F, Wolff D, Bauer L, Wertz HJ, Wenz F, Lohr F: Reirradiation of spinal column metastases: comparison of several treatment techniques and dosimetric validation for the use of VMAT. Strahlenther Onkol 2011, 187:406–415.

33. Wang X, Krishnan S, Zhang X, et al: Proton radiotherapy for liver tumors: dosimetric advantages over photon plans. Med Dosim 2008, 33:259–267.